ALFA Finder| Revenue growth | FY26 revenue up 36% YoY to ₹503cr; Q4FY26 revenue up 35.8%. |
|---|---|
| Margins | EBITDA margins rising towards 30% target via regulated market mix. |
| Demand visibility | Strong registration pipeline in Germany, Mexico, and Colombia for growth. |
| Management confidence | Confident in meeting ₹1,000cr FY29 goal using oncology and biosimilars. |
Growth
FY26 revenue reached ₹503cr (+36% YoY); PAT grew 69% to ₹67cr; EBITDA margins expanded to 24%.
Outlook
Guided FY27 revenue of ₹650cr and PAT ₹100cr. Long-term target ₹1,000cr by FY29 with 30% EBITDA.
Risks
Geopolitical disruptions in Middle East impacting working capital cycles; regulatory delays in registration timelines for regulated markets.
Earnings Call filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,020.00
- Market cap
- ₹4,171 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 51.5×Sector 43.8×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Board Meeting Date
Kwality Pharmaceuticals will hold a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter and half-year ended September 2026.
Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.